Nanologica Raises Capital Through Fully Subscribed Directed Share Issues

Nanologica AB ( (SE:NICA) ) has provided an announcement.

Nanologica AB has completed two directed share issues totaling 34,203,780 new shares, all of which were subscribed and allotted as planned. The issues, priced at SEK 0.40 per share, strengthen the company’s capital base as it pursues growth in its niche market for peptide drug purification solutions.

Ardena Sweden AB received all 21,453,780 shares in a set‑off issue valued at about SEK 8.6 million, while a limited group of investors subscribed to 12,750,000 shares, providing roughly SEK 5.1 million in cash proceeds before issue costs. The transactions enhance Nanologica’s financial flexibility and deepen its strategic relationship with Ardena, potentially supporting future operational and commercial expansion.

The most recent analyst rating on (SE:NICA) stock is a Sell with a SEK0.36 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.

More about Nanologica AB

Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells advanced chromatographic consumables to pharmaceutical manufacturers. Its products are designed for purification of peptide drugs such as insulin and GLP‑1 analogues, aiming to boost productivity and cut costs in a growing global niche driven by rising diabetes and obesity treatments.

Average Trading Volume: 191,481

Technical Sentiment Signal: Sell

Current Market Cap: SEK113.1M

See more data about NICA stock on TipRanks’ Stock Analysis page.